title: Response to trans-retinoic acid in an AMLM3 patient resistant to cis-retinoic acid.
authors.forename: D
authors.initials: D
authors.lastname: McCarthy
authors.forename: D
authors.initials: D
authors.lastname: Samson
authors.forename: N
authors.initials: N
authors.lastname: Mir
authors.forename: S
authors.initials: S
authors.lastname: Rule
authors.forename: F
authors.initials: F
authors.lastname: Nadir
authors.forename: J
authors.initials: J
authors.lastname: Taylor
authors.forename: C
authors.initials: C
authors.lastname: Costello
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D013237:Stereoisomerism; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D003561:Cytarabine; D014212:Tretinoin; D005047:Etoposide; D008130:Lomustine; D003630:Daunorubicin